AMLX — Amylyx Pharmaceuticals, Inc.

Summary of Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended Q4 2025 with $317 million in cash and marketable securities, down from $344 million in Q3 2025, providing a cash runway into 2028.
• Operating Expenses: Total operating expenses were $36.6 million, an 8% decrease from Q4 2024.
  • R&D Expenses: $21.2 million, down from $22.9 million in Q4 2024, primarily due to reduced spending on AMX035 for ALS.
  • SG&A Expenses: $15.4 million, down from $17.1 million in Q4 2024, attributed to decreased consulting and professional services.
• Stock-Based Compensation: Non-cash stock-based compensation was $6.4 million, slightly down from $6.8 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Pipeline Progress:
  • Initiated the pivotal Phase III LUCIDITY trial for Avexatide, targeting post-bariatric hypoglycemia (PBH).
  • Announced AMX318 as a development candidate for PBH and other rare diseases.
  • AMX114 received Fast Track designation and advanced to the next cohort in the Phase 1 LUMINA trial for ALS.
• Commercial Preparations: Focused on building commercial infrastructure and strategies for Avexatide, including market research and key hires to support a potential launch in 2027.

3. Forward Guidance and Outlook

• LUCIDITY Trial: Expect top-line data in Q3 2026, with full enrollment anticipated to complete shortly.
• NDA Readiness: Actively preparing NDA sections to expedite submission post-trial results.
• Market Opportunity: Estimated 160,000 individuals in the U.S. have PBH, indicating a significant market potential for Avexatide.

4. Bad News, Challenges, or Points of Concern

• Cash Decrease: The decline in cash reserves from the previous quarter may raise concerns about funding for ongoing projects.
• Market Competition: The absence of approved therapies for PBH poses both an opportunity and a risk, as any future competitors could enter the market.
• Clinical Trial Risks: The potential for variability in patient responses and the challenge of achieving statistically significant results in the LUCIDITY trial remain concerns.

5. Notable Q&A Insights

• Clinical Trial Execution: Executing the LUCIDITY trial has highlighted the significant unmet need in PBH, with clinicians expressing the urgency for effective treatments.
• Placebo Response: The team anticipates a low placebo response based on historical data, which supports their confidence in Avexatide's efficacy.
• Market Research Findings: Insights from discussions with physicians indicate a strong interest in reducing hypoglycemic events, particularly level 3 emergencies, which are viewed as critical.
• ICD-10 Code for PBH: The potential introduction of an ICD-10 code for PBH is seen as a positive development that could enhance awareness and treatment pathways, although not essential for reimbursement.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and notable insights from the Q&A, providing a comprehensive overview of Amylyx Pharmaceuticals’ current standing and future direction.